Akebia Ther

Yahoo Finance • 15 days ago

Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors

CAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of bio... Full story

Yahoo Finance • 2 months ago

Here are the major earnings before the open Thursday

Major earnings expected before the bell on Thursday include: * Viatris (VTRS [https://seekingalpha.com/symbol/VTRS]) * Baidu (BIDU [https://seekingalpha.com/symbol/BIDU]) * Vistance Networks (VISN [https://seekingalpha.com/symbol/VI... Full story

Yahoo Finance • 2 months ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, February 26, 2... Full story

Yahoo Finance • 4 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees optio... Full story

Yahoo Finance • 4 months ago

Akebia Announces Establishment of Rare Kidney Disease Pipeline

Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications Phase 2 trial of Praliciguat... Full story

Yahoo Finance • 5 months ago

Akebia signals 7x increase in patient access for Vafseo entering 2026 amid operational focus

Earnings Call Insights: Akebia Therapeutics (AKBA) Q3 2025 MANAGEMENT VIEW * John Butler, CEO, highlighted that "through 41 weeks of launch, Vafseo has generated more total prescriptions than any recent launch in dialysis." He acknowle... Full story

Yahoo Finance • 5 months ago

Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs

CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the presentation of a p... Full story

Yahoo Finance • 6 months ago

Biggest stock movers Wednesday: JOBY, ENPH, and more

[Emerging Financial Data - Stock Market, Prosperity, Bull Market - Blue Version] DKosig Stock futures inched up Wednesday morning as investors awaited the Federal Reserve’s interest rate decision and key earnings reports from major techno... Full story

Yahoo Finance • 6 months ago

Akebia plummets as it abandons Vafseo for non-dialysis patients

[Red arrow pointing down with declining bar graph on red background] lerbank * After the US FDA rebuffed its plans on a trial design, Akebia Therapeutics (NASDAQ:AKBA [https://seekingalpha.com/symbol/AKBA]) has decided to abandon effort... Full story

Yahoo Finance • 6 months ago

Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients

CAMBRIDGE, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that after meeting with... Full story

Yahoo Finance • 6 months ago

Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025

CAMBRIDGE, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present da... Full story

Yahoo Finance • 7 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees opti... Full story

Yahoo Finance • 8 months ago

Akebia GAAP EPS of $0.00 beats by $0.02, revenue of $62.47M beats by $15.23M

* Akebia press release [https://seekingalpha.com/pr/20192771-akebia-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business] (NASDAQ:AKBA [https://seekingalpha.com/symbol/AKBA]): Q2 GAAP EPS of $0.00 beats by $0.02... Full story

Yahoo Finance • 9 months ago

Akebia Therapeutics (AKBA) Kidney Therapy Vafseo Gaining Market Share

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the best high-return penny stocks to buy now. On July 14, 2025, Akebia shared key updates during the H.C. Wainwright Kidney Conference, emphasizing the rollout of its oral anemia treatment... Full story

Yahoo Finance • 9 months ago

Catalyst Watch: Bank earnings rush, OPEC report, Tesla EVs get Grok, and Superman at the box office

[Wall Street sign in Lower Manhattan, NYC] georgeclerk Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MO... Full story

Yahoo Finance • 9 months ago

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Nik Grund, Chief C... Full story

Yahoo Finance • 9 months ago

Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 13 Stocks Under $5 With High Upside Potential. On May 29, Leerink Partners analyst Roanna Ruiz maintained a Buy rating on Akebia Therapeutics, Inc. (NASDAQ:AKBA) and set a price target... Full story

Yahoo Finance • 11 months ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Akebia Executive Ma... Full story

Yahoo Finance • last year

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present d... Full story

Yahoo Finance • last year

Why Akebia Therapeutics Inc. (AKBA) Went Down On Thursday?

We recently published a list of Thursday’s 10 Worst-Performing Stocks. In this article, we are going to take a look at where Akebia Therapeutics Inc. (NASDAQ:AKBA) stands against other Thursday’s worst-performing stocks. Wall Street’s mai... Full story